Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...fehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist.
more
Autres troubles
Chapitre H.1
Edition en français
Traduction : Priscille Gérardin et Malaïka Lasfar Sous la direction de : Priscille Gérardin Avec le soutien de la SFPEADA
Introduction
Chapitre A.4
Edition en français Traduction : Eleanor O’Boyle
Sous la direction de : Priscille Gérardin
Avec le soutien de la SFPEADA
PLoS Medicine Vol. 6 no. 10 (2009) e1000165
Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed
to support decision making. A countrywide mass vaccination campaign with the
use of an inactivated severe acute respiratory syndrome c...oronavirus 2 (SARS-CoV-2)
vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021.
more
В этой главе мы попытаемся представить современные взгляды на классификацию, эпидемиологию, этиологию, клиническую картину, оценку, прогноз и лечение РАС. Мы надее...мся, что данные материалы
окажутся полезными врачам, активно настроенным на изменение в глобальном масштабе отношения к этой группе пациентов и их семьям.
more
Trastornos del desarrollo
Capítulo C.2
Traducción de la versión inglesa del 2014
Manual de Salud Mental Infantil y Adolescente de la IACAPAP
Troubles du Développement
Chapitre C.2
Autres troubles
Chapitre H.4
Antimicrobials are widely used in food animal production, and use is rapidly increasing.
In an era of growing demand for animal products, there is an increasing trend towards the industrial production of food animals, especially in lower- and middle-income countries (LMICs). One hallmark of this me...thod of animal production is the
use of antimicrobial drugs, which in the majority of cases are administered to healthy animals for purposes other than
treating or controlling disease (termed “therapeutic uses”)
more
Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical t...reatment of CE.
more
Opinión y análisis / Opinion and analysis
Rev Panam Salud Publica 38(3), 2015; Int J Tuberc Lung Dis. 2015;19(4):375–80
Other disorders
Chapter H.5
SADJ August 2016, Vol 71 no 7 p314 - p318
Clinical Review
ПРактИЧеское РукоВодстВо для соВместных меРоПРИятИй.
Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ...strongly linked to an increase risk of PAD. Although PAD has been historically underappreciated compared to coronary artery disease and stroke, greater attention on PAD in recent years has led to important new epidemiologic insights in the areas of thrombosis, inflammation, dyslipidemia, and microvascular disease. In addition, the concept of polyvascular disease, or clinically-evident atherosclerosis in multiple arterial beds, is increasingly identified as a particularly malignant cardiovascular disease worthy of special clinical attention and further study. It is noteworthy that PAD may increase the risk of adverse outcomes in similar or even greater magnitude than coronary disease or stroke. In this review, we highlight important new advances in the epidemiology of PAD with a particular focus on polyvascular disease, emerging biomarkers, and differential risk pathways for PAD compared to other atherosclerotic diseases.
more
PHA 2018; 8(S1): S24–S28
© 2018 The Union
Volume 2 · Supplement 4 · November 2016
ISSN 2055-66-40 – Print
Foreword
| ISSN 2055-66-59 – Online
www.viruseradication.com